MRNA vaccine takes on glioblastoma in first human trial
NCT ID NCT05938387
First seen Feb 27, 2026 · Last updated Jun 19, 2026 · Updated 17 times
Summary
This early-stage trial tested an mRNA vaccine called CVGBM in 37 people with a type of aggressive brain cancer called glioblastoma. The vaccine aims to help the immune system recognize and fight cancer cells. The main goal was to check safety and find the right dose, with some early looks at whether it might delay the cancer's return.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU de Liège
Liège, Belgium
-
Erasmusmc Cancer institute
Rotterdam, South Holland, Netherlands
-
Neurosurgical Clinic at the LMU Munich
München, Germany
-
Universitair Ziekenhuis Brussel - PPDS
Brussels, Belgium
-
Universitatsklinikum Leipzig
Leipzig, Saxony, Germany
-
University Clinic Heidelberg
Heidelberg, Baden-Wurttemberg, Germany
-
University Clinic Regensburg
Regensburg, Bavaria, Germany
-
University Hospital Essen
Essen, North Rhine-Westphalia, Germany
-
Universitätsklinikum Bonn
Bonn, North Rhine-Westphalia, Germany
-
Universitätsklinikum Frankfurt
Frankfurt am Main, Hesse, Germany
-
Universitätsklinikum Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, Germany
-
Universitätsklinikum Tübingen
Tübingen, Baden-Wurttemberg, Germany
-
Universitätsmedizin Mannheim
Mannheim, Baden-Wurttemberg, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CVGBM mRNA vaccine
What this could lead to
If this works, it could point toward a new way to treat glioblastoma, an aggressive brain cancer, by training the immune system to attack tumor cells.
What could go wrong
This is a very early, small phase 1 trial focused on safety, not effectiveness. The vaccine may not work, and side effects are unknown. It also only applies to patients with a specific genetic profile.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.